Genetic polymorphisms of prostacyclin synthase gene and cardiovascular disease

International Angiology

Volumn 29, Issue 2 SUPPL. 1, 2010, Pages 33-42

  Nakayama, T ^a  

^a NIHON UNIVERSITY   (Japan)

Author keywords

Beraprost sodium; Cardiovascular diseases, prevention and control; Mutation; Polymorphism; Prostacyclin

Indexed keywords

9 DEOXY 9ALPHA,6 NITRILO 15 (4 PROPYLCYCLOHEXYL) 16,17,18,19,20 PENTANORPROSTAGLANDIN F1 ALPHA METHYL ESTER; BERAPROST; CREATININE; CYCLIC AMP; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTACYCLIN SYNTHASE; UREA;

ANKLE BRACHIAL INDEX; ARTERIAL STIFFNESS; BLOOD VESSEL INJURY; BRAIN BLOOD FLOW; BRAIN EMBOLISM; BRAIN INFARCTION; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY FLOW; CELL PROTECTION; CONNECTIVE TISSUE DISEASE; CORPUS LUTEUM; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DNA SEQUENCE; DRUG ABSORPTION; DRUG APPROVAL; DRUG FECES LEVEL; DRUG STABILITY; DRUG URINE LEVEL; DRUG WITHDRAWAL; DYSPNEA; EMBOLISM; ESSENTIAL HYPERTENSION; EXERCISE; EXON; FIBRINOLYSIS; FIBROMUSCULAR DYSPLASIA; GENE FREQUENCY; GENE LOCATION; GENE LOCUS; GENE MUTATION; GENE STRUCTURE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HEADACHE; HEART INFARCTION; HEART RATE; HEART RIGHT VENTRICLE FAILURE; HEMODYNAMICS; HUMAN; JAW; KIDNEY CORTEX; KIDNEY INJURY; LONG TERM CARE; LUNG; LUNG ARTERY PRESSURE; MEMORY DISORDER; MICROTHROMBUS; MORTALITY; NEUTROPHIL CHEMOTAXIS; NONHUMAN; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; PAIN; PULMONARY HYPERTENSION; PULSE WAVE; QUALITY OF LIFE; REVIEW; SMOOTH MUSCLE FIBER; SPLEEN; STOMACH; STROKE; SURVIVAL; TESTIS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOSIS; UREA BLOOD LEVEL; UTERUS; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; VASODILATATION; WALKING;

ADULT; AGED; ANIMALS; BASE SEQUENCE; CARDIOVASCULAR DISEASES; CEREBRAL INFARCTION; CYTOCHROME P-450 ENZYME SYSTEM; EPOPROSTENOL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION; INDIVIDUALIZED MEDICINE; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; MYOCARDIAL INFARCTION; PATIENT SELECTION; PEDIGREE; PHENOTYPE; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; RISK FACTORS; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 77953564062     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Bunting S, Gryglewski R, Moncada S, Vane JR. Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation. Prostaglandins 1976;12:897-913.
2. 2). Prostaglandins 1976;12:915-28.
3. Moncada S, Vane JR. Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N Engl J Med 1979;300:1142-7. (Pubitemid 9175616)
4. Schafer AI, Cooper BO, Hara D, Handin RI. Identification of platelet receptors for prostaglandin I2 and D2. J Biol Chem 1979;254:2914-7.
5. Siegl AM, Smith JB, Silver MJ, Nicolaou KC, Ahern D. Selective binding site for [3H]prostacyclin on platelets. J Clin Invest 1979;63:215-20.
6. Gorman RR, Fitzpatrick FA, Miller OV. Reciprocal regulation of human platelet cAMP levels by thromboxane A2 and prostacyclin. Adv Cyclic Nucleotide Res 1978;9:597-609.
7. Tateson JE, Moncada S, Vane JR. Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins 1977;13:389-99.
8. Miller OV, Aiken JW, Hemker DP, Shebuski RJ, Gorman RR. Prostacyclin stimulation of dog arterial cyclic AMP levels. Prostaglandins 1979;18:915-25.
9. Moncada S, Vane JR. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev 1979;30:293-331. (Pubitemid 10198932)
10. Graf H, Ullrich V. In Hietanen E, Lairinen M, Heanninen O, editors. Cytochrome P450. Biochemistry, biophysics and environmental implications Amsterdam: Elsevier; 1982. p. 103-6.
11. Ullrich V, Castle L, Weber P. Spectral evidence for the cytochrome P450 nature of prostacyclin synthase. Biochem Pharmacol 1981;30:2033-20336.
12. DeWitt DL, Smith WL. Purification of prostacyclin synthase from bovine aorta by immunoaffinity chromatography. Evidence that the enzyme is a hemoprotein. J Biol Chem 1983;258:3285-93.
13. Inoue M, Smith WL, DeWitt DL. Molecular characterization of the prostacyclin synthase. Adv Prostaglandin Thromboxane Leukouicne Res 1987;17:29-33.
14. Pereira B, Wu KK, Wang L-H. Bovine prostacyclin synthase: purification and isolation of partial cDNA. Biochem Biophys Res Commun 1993;197:1041-8.
15. Nakayama T. Diversity of prostacyclin and future outlook. Medical Review, Tokyo 2002;1:298-307. (in Japanese)
16. Nakayama T, Soma M, Izumi Y, Kanmatsuse K. Organization of the human prostacyclin synthase gene. Biochem Biophys Res Commun 1996;221:803-6.
17. Nakayama T, Soma M, Takahashi Y, Uwabo J, Izumi Y, Kanmatsuse K. Novel polymorphic CA/TG repeat identified in the human prostacyclin synthase gene. Hum Hered 1997;47:176-7.
18. Nakayama T, Soma M, Rahmurula D, Izumi Y, Kanmatsuse K. Nonsense mutation of prostacyclin synthase gene in a family. Lancet 1997;349:1887-8.
19. Nakayama T, Soma M, Kanmatsuse K. Amplification of 5?-flanking region of human prostacyclin synthase gene and novel polymorphism. Nihon University Journal of Medicine 1998;57:24-28. (in Japanese)
20. Nakayama T, Soma M, Rehemudula D, Takahashi Y, Tobe H, Sato MN et al. Association of 5? upstream promoter region of prostacyclin synthase gene variant with cerebral infarction. Am J Hypertens 2000;13:1263-7.
21. Nakayama T, Soma M, Saito S, Honye J, Yajima J, Rahmutula D et al. Association of a novel single nucleotide polymorphism of the prostacyclin synthase gene with myocardial infarction. Am Heart J 2002;143:797-801.
22. Nakayama T, Soma M, Watanabe Y, Hasimu B, Sato M, Aoi N et al. Splicing mutation of the prostacyclin synthase gene in a family associated with hypertension. Biochem Biophys Res Commun 2002;297:1135-9.
23. Moncada S, Gryglewski RJ, Bunting S, Vane J. An enzyme isolated from arteries that inhibits platelet aggregation. Nature 1976;263:663-5.
24. Dembinska-Kiec A, Kostka-Trabka E, Gryglewski RJ. Effect of prostacyclin on fibrinolytic activity in patients with arteriosclerosis obliterans. Thromb Haemostas 1982;47:190. (Pubitemid 12161168)
25. Chapleau DE, White RP. Effects of prostacyclin on the canine isolated basilar artery. Prostaglandins 1979;17:573-80.
26. 2 in recurring reduction of carotid and cerebral flow in dogs. Stroke 1981;2:786-92. (Pubitemid 12227373)
27. 2, indomethacin, and heparin promote postischemic neuronal recovery in dogs. Ann Neurol 1982;12:145-56.
28. Vane JR. Prostaglandins and the cardiovascular system. Br Heart J 1983;49:405-9.
29. Stier CT Jr, Chander PN, Belmonte A, Inamdar RS, Mistry M. Beneficial action of beraprost sodium, a prostacyclin analog, in stroke-prone rats. J Cardiov Pharmacol 1997;30:285-93.
30. Uchiyama-Tsuyuki Y, Kawashima K, Araki H, Otomo S. Prostacyclin analog TTC-909 reduces memory impairment in rats with cerebral embolism. Pharmacol Biochem Behav 1995;3:555-9.
31. Masuda Y, Yasuba M, Zushi K, Ochi Y, Kadokawa T, Okegawa T. Effect of OP 2507, a stable prostacyclin analog on cerebral ischemia induced by unilateral ligation of common carotid artery in gerbils. Arch Int Pnarmacodyn Ther 1988;294:125-36.
32. Martin JF, Hamdy N, Nicholl J, Lewtas N, Bergvall U, Owen P, et al. Double-blind controlled trial of prostacyclin in cerebral infarction. Stroke 1985;16:386-90. (Pubitemid 15034417)
33. Hsu CY, Faught RE Jr, Furlan AJ, Coull BM, Huang DC, Hogan EL, et al. Intravenous prostacyclin in acute non-hemorrhagic stroke: a placebo-controlled double-blind trial. Stroke 1987;18:352-8.
34. Sitbon O, Humbert M, Simonneau G. Primary pulmonary hypertension: current therapy. Prog Cardiovasc Dis 2002;45:115-28.
35. 2 derivatives and their inhibitory activities to human platelet aggregation. Adv Prostaglandin Thromboxane. Leukot Res 1985;15:279-81.
36. 2 analogue. Jpn J Pharmacol 1987;43:81-90. (Pubitemid 17207613)
37. Umetsu T, Murata T, Nishio S. Studies on the antiplatelet effect of the stable epoprostenol analogue beraprost sodium and its mechanism of action in rats. Arzneim-Frorsch 1989;39:68-73. (Pubitemid 19030789)
38. Akiba T, Miyazaki M, Toda, T. Vasodilator actions of TRK-100, a new prostaglandin 12 analogue. Br J Pharmacol 1986;89:703-11. (Pubitemid 17200576)
39. Kainoh M, Imai R, Umetsu T, Hattori M, Nishio S. Prostacyclin and beraprost sodium as suppressors of activated rat polymorphonuclear leukocytes. Biochem Pharmacol 1990;39:477-84.
40. Kajikawa N, Nogimori K, Murata T, Nishio S, Uchiyama S. Specific binding of the new stable epoprostenol analogue beraprost sodium to prostacyclin receptors on human and rat platelets. Arzneimittelforschung 1989;39:495-9. (Pubitemid 19099280)
41. Murata T, Murai T, Kanai T, Ogaki Y, Sanai K, Kanda H, Sato S, Kajikawa N, Umetsu T, Matsuura H. General pharmacology of beraprost sodium. 2nd communication: effect on the autonomic, cardiovascular and gastrointestinal systems, and other effects. Arzneimittelforschung 1989;39:867-76.
42. Olschewski H, Rose F, Schermuly RH, Ghofrani A, Enke B, Olschewski A, Seeger W. Prostacyclin and its analogues in the treatment of pulmonary hypertension. Pharmacol Ther 2004;102:139-53.
43. 2 analogue, beraprost, in primary and secondary pulmonary hypertension. Am J Cardiol 1996;78:244-7.
44. Okano Y, Yoshioka T, Shimouchi A, Satoh T, Kunieda T. Orally active prostacyclin analogue in primary pulmonary hypertension. Lancet 1997;349:1365. (Pubitemid 27197541)
45. Nagaya N, Uematsu M, Okano Y, Satoh T, Kyotani S, Sakamaki F, Nakanishi N, Miyatake K, Kunieda T. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol 1999;34:1188-92.
46. Galie N, Humbert M, Vachiery JL, Vizza CD, Kneussl M, Manes A, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. Am Coll Cardiol 2002;39:1496-502.
47. Nakayama T, Hironaga T, Ishima H, Maruyama T, Masubuchi Y, Kokubun S. The prostacyclin analogue beraprost sodium prevents development of arterial stiffness in elderly patients with cerebral infarction. Prostagland Leukot Essent Fatty Acids 2004;70:491-4.
48. Miyata A, Hara S, Yokoyama C, Inoue H, Ullrich V, Tanabe T. Molecular cloning and expression of human prostacyclin synthase. Biochem Biophys Res Commun 1994;200:1728-34.
49. Yokoyama C, Yabuki T, Inoue H, Tone Y, Hara S, Hatae T et al. Human gene encoding prostacyclin synthase (PTGIS): genomic organization, chromosomal localization, and promoter activity. Genomics 1996;36:296-304.
50. Jeremy JY. Barradas MA. Craft IL, Mikhailidis DP. Dandona P. Does human placenta produce prostacyclin? Placenta 1985;6:45-52.
51. Murata T, Ushikubi F, Matsuoka T, Hirata M, Yamasaki A, Sugimoto et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 1997;388:678-82.
52. Yokoyama C, Yabuki T, Shimonishi M, Wada M, Hatae T, Ohkawara S et al. Prostacyclin-deficient mice develop ischemic renal disorders, including nephrosclerosis and renal infarction. Circulation 2002;106:2397-403.
53. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ et al. P450 superfamily: up-date on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996;6:1-42.
54. Hatae T, Hara S, Yokoyama C, Yabuki T, Inoue H, Ullrich V et al. Site-directed mutagenesis of human prostacyclin synthase: alteration of Cys441 of the Cys-pocket, and Glu347 and Arg350 of the EXXR motif. FEBS Lett 1996;389:268-72.
55. Shyue SK, Ruan KH, Wang LH, Wu KK. Prostacyclin synthase active sites. Identification by molecular modeling-guided site-directed mutagenesis. J Biol Chem 1997;272:3657-62.
56. Nakayama T, Soma M, Rahmutula D, Tobe H, Sato M, Uwabo J et at. Association study between a novel single nucleotide polymorphism of the promoter region of the prostacyclin synthase gene and essential hypertension. Hypertens Res 2002;25:65-8.
57. Nakayama T, Soma M, Takahashi Y, Rahmutula D, Tobe H, Sato M et al. Polymorphism of the promoter region of prostacyclin synthase gene is not associated with essential hypertension. Am J Hypertens 2001;14:409-11.
58. Iwai N, Katsuya T, Ishikawa K, Mannami T, Ogata J, Higaki J et al. Human prostacyclin synthase gene and hypertension. The Suita study. Circulation 1999;100:2231-6.
59. Hashimoto K, Ishibashi K, Gebretsadik T, Hartert TV, Yamamoto A, Nakayama T et al. Functional polymorphism of the promoter region of the prostacyclin synthase gene and severity of RSV infection in hospitalized children. J Med Virol 2008;80:2015-22.
60. Nakayama T, Soma M, Kanmatsuse K. Organization of the human prostacyclin synthase gene and association analysis of a novel CA repeat in essential hypertension. Adv Exp Med Biol 1997;433:127-30. (Pubitemid 28231798)
61. Barbaliç M, Naranciç NS, Skariç-Juriç T, Salihoviç MP, Klariç IM, Lauc LB et al. A quantitative trait locus for SBP maps near KCNB1 and PTGIS in a population isolate. Am J Hypertens 2009;22:663-8.
62. Arzilli F, Giovannetti R, Lenzi M, Salvetti A. Acute hemodynamic (systemic and renal) and humoral effects of three increasing doses of iloprost in essential hypertensives. Am J Hypertens 1989;11:856-60. (Pubitemid 19267652)
63. Henriksson P, Edhag O, Wennmalm A. Prostacyclin infusion in patients with acute myocardial infarction. Br Heart J 1985;53:173-9. (Pubitemid 15053138)
64. 2 synthase. Hypertension Navigator Vol. 1, Medical Review, Tokyo 2000;70-1. (in Japanese)
65. Narumiya S. Sugimoto Y. Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999;79:1193-226.
66. de Leeuw PW. Nonsteroidal anti-inflammatory drugs and hypertension. The risks in perspective. Drugs 1996;51:179-87.
67. Nakayama T, Hironaga T, Ishima H, Maruyama T, Masubuchi Y, Kokubun S. The prostacyclin analogue beraprost sodium prevents development of arterial stiffness in elderly patients with cerebral infarction. Prostaglandins Leukot Essent Fatty Acids 2004;70:491-4.